4.5: Pharmacodynamics & Receptor Theory

4.5 Pharmacodynamics & Receptor Theory

Pharmacodynamics describes what a drug does to the body, exploring the biochemical, physiological, and molecular effects of drugs and their mechanisms of action. Central to this discipline is receptor theory, which assumes that drugs interact with specific macromolecular components of the cell (receptors) to initiate a cascade of signals that result in a pharmacological effect.

---

Receptor Binding: Affinity vs. Efficacy

Receptors are typically proteins located on cell membranes or within the cytoplasm/nucleus. The interaction between a drug (ligand) and a receptor is governed by two distinct properties: affinity and efficacy (intrinsic activity).

Affinity

Affinity is the chemical force that attracts a drug to its receptor and governs the binding interaction. It is quantified by the equilibrium dissociation constant (Kd), which represents the drug concentration required to occupy 50% of the total receptor population at equilibrium.

• High Affinity: A drug with high affinity has a very low Kd value. It binds tightly and requires low concentrations to achieve high receptor occupancy.
• Low Affinity: A drug with low affinity has a high Kd value, requiring much higher concentrations to bind the same number of receptors.

Efficacy (Intrinsic Activity)

Efficacy is the ability of a drug, once bound, to induce a conformational change in the receptor that activates downstream cellular signaling pathways to produce a biological effect.

• A drug can have high affinity but zero efficacy (meaning it binds tightly but does not activate the receptor).
• Efficacy is the main factor that determines the clinical effectiveness of a drug.

---

Agonists: Full, Partial, and Inverse

Drugs that bind to receptors and initiate a response are classified as agonists. Depending on their ability to activate the receptor and the direction of the response, they are categorised into three main groups:

• Full Agonists: Bind to a receptor and produce the maximal response achievable from that receptor system. They have an intrinsic activity of 1 (or 100%).
  • Example: Morphine and fentanyl are full agonists at the mu-opioid receptor, producing maximum analgesia and respiratory depression.
  • Example: Salbutamol is a full agonist at beta-2 adrenergic receptors, causing maximal bronchodilation.
• Partial Agonists: Bind to a receptor at the same site as a full agonist but produce only a submaximal response, even when 100% of the receptors are occupied. Their intrinsic activity is between 0 and 1.
  • Clinical Duality: A partial agonist acts as an agonist when no full agonist is present. However, in the presence of a full agonist, it acts as a competitive antagonist. Because it has a high affinity, it displaces the full agonist from the receptors, but because of its lower efficacy, it reduces the overall biological response.
  • Example: Buprenorphine is a partial mu-opioid agonist. In a patient using heroin or morphine (full agonists), administering buprenorphine will displace the full agonist, resulting in a sudden drop in receptor activation. This can precipitate acute withdrawal symptoms. However, in an opioid-naive patient, buprenorphine acts as an agonist, providing mild analgesia.
  • Example: Aripiprazole is a partial agonist at dopamine D2 receptors, stabilizing dopamine activity in schizophrenia (blocking excess dopamine in hyperactive pathways while providing baseline stimulation in hypoactive pathways).
• Inverse Agonists: Many receptor systems exhibit constitutive activity, meaning a fraction of the receptors exist in the active conformation and generate a baseline signal even in the complete absence of an agonist. An inverse agonist binds to the same active site as an agonist but selectively stabilises the inactive conformation of the receptor. This shifts the equilibrium away from the active state, reducing the baseline signal below the constitutive level. Its intrinsic activity is negative (between 0 and -1).
  • Example: Antihistamines like cetirizine or loratadine are inverse agonists at H1 histamine receptors. They do not just block histamine; they actively turn off the baseline constitutive signaling of the H1 receptor, which reduces allergic symptoms.
  • Example: Beta-carbolines bind to the GABA-A receptor and act as inverse agonists, inducing anxiety and convulsions, which are opposite to the sedative effects of GABA-A agonists (like benzodiazepines).

---

Antagonists: Competitive, Non-competitive, and Irreversible

Antagonists bind to receptors but do not activate them (intrinsic activity = 0). Their primary clinical effect is to block the actions of endogenous neurotransmitters or exogenous agonists.

Competitive Antagonists

• Mechanism: Binds reversibly to the exact same active (orthosteric) site as the agonist.
• Overcoming the Blockade: Because the binding is reversible and competitive, the blockade can be completely overcome by increasing the concentration of the agonist. The agonist outcompetes the antagonist for the binding sites.
• Effect on Dose-Response Curve: Shifts the log dose-response curve of the agonist to the right in a parallel fashion. The maximum response (Emax) is unchanged, but the EC50 is increased. This represents a decrease in the agonist's potency, but no change in its efficacy.
• Example: Naloxone is a competitive antagonist at opioid receptors used to reverse opioid overdose. Metoprolol is a competitive antagonist at beta-1 receptors.

Non-competitive Antagonists

• Mechanism: Binds reversibly to an allosteric site (a site separate from the agonist's active binding site). This binding causes a conformational change in the receptor that prevents the agonist from activating it.
• Overcoming the Blockade: Increasing the agonist concentration cannot overcome the blockade because the agonist and antagonist are not competing for the same site.
• Effect on Dose-Response Curve: Shifts the log dose-response curve downwards. The maximum response (Emax) is reduced (efficacy decreases). The EC50 may remain unchanged or shift slightly to the right.
• Example: Ketamine acts as a non-competitive antagonist at the NMDA glutamate receptor.

Irreversible Antagonists

• Mechanism: Binds covalently or with extremely high affinity to the active site of the receptor. Once bound, the antagonist cannot dissociate.
• Overcoming the Blockade: Increasing the agonist concentration cannot displace the irreversible antagonist. The blockade can only be overcome by the synthesis of new receptors by the cell, which takes days.
• Effect on Dose-Response Curve: Similar to non-competitive antagonists, it reduces Emax and flattens the dose-response curve. However, if there are spare receptors (more receptors than needed to elicit a maximal response), a low concentration of irreversible antagonist may initially cause a parallel rightward shift (like a competitive antagonist) without reducing Emax. Once the spare receptors are fully occupied, further increases in antagonist concentration will drop the Emax.
• Example: Phenoxybenzamine is an irreversible alpha-adrenergic antagonist used in pheochromocytoma. Aspirin covalently acetylates COX-1 enzymes, leading to irreversible inhibition for the lifespan of the platelet.

---

Dose-Response Curves: Potency vs. Efficacy

A dose-response curve plots the magnitude of the pharmacological effect against the drug dose or concentration. When plotted on a logarithmic scale, it typically forms a symmetrical sigmoidal (S-shaped) curve.

Potency

Potency refers to the amount of drug required to produce an effect of a given intensity. It is represented along the horizontal axis of the dose-response curve and is quantified by the EC50 (effective concentration 50%) or ED50 (effective dose 50%), which is the concentration/dose that produces 50% of the drug's maximal effect.

• A drug with a lower EC50 is more potent because less drug is needed to produce the same effect.
• Example: Fentanyl is far more potent than morphine; a dose of 100 micrograms of fentanyl produces analgesia equivalent to 10 milligrams of morphine.

Efficacy (Emax)

Efficacy refers to the maximal response that a drug can elicit, represented by the plateau (height) of the dose-response curve (Emax).

• Efficacy is clinically more important than potency. If a patient has severe pain, a highly effective drug (like morphine) is required. A less effective drug (like paracetamol) will not control the pain, no matter how much the dose is increased, because its Emax is lower.

---

Therapeutic Index and Safety Margin

The Therapeutic Index (TI) is a quantitative comparison of the dose of a drug required to produce its therapeutic effect relative to the dose that produces toxicity.

Preclinical Calculation

In animal studies, the Therapeutic Index is calculated as:

TI = LD50 / ED50

Where:

• LD50 is the median lethal dose (dose that is lethal to 50% of the population).
• ED50 is the median effective dose (dose that produces the desired therapeutic effect in 50% of the population).

In clinical practice, where lethality is not a standard endpoint, we use the Median Toxic Dose (TD50):

TI = TD50 / ED50

Narrow vs. Wide Therapeutic Index

• Wide Therapeutic Index: The toxic dose is much larger than the therapeutic dose. These drugs are highly safe.
  • Example: Penicillin has a very wide therapeutic index; doses can be increased significantly without causing direct cellular toxicity.
• Narrow Therapeutic Index (NTI): The margin between the effective dose and the toxic dose is very narrow. A small increase in dose or a drug-drug interaction that increases plasma levels can lead to severe toxicity.
  • Examples: Lithium, digoxin, warfarin, phenytoin, cyclosporin, gentamicin, theophylline.
  • Clinical Management: These drugs require strict clinical oversight:
    1. Therapeutic Drug Monitoring (TDM) to measure serum concentrations.
    2. Gradual dose titration.
    3. Routine monitoring of physiological markers (e.g., INR for warfarin, serum creatinine/electrolytes for lithium and digoxin).
    4. Comprehensive patient education regarding early signs of toxicity (e.g., visual disturbances for digoxin; coarse hand tremors for lithium).